A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control...

Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

cover image Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2024 About Prime Therapeutics Prime Therapeutics...